FDA Puts Partial Hold on AbbVie's Venetoclax Clinical Trials for Multiple Myeloma
March 19 2019 - 10:04AM
Dow Jones News
By Allison Prang
The U.S. Food and Drug Administration has put a partial clinical
hold on AbbVie Inc.'s (ABBV) clinical trials for using venetoclax
for multiple myeloma, the company said.
AbbVie said the FDA's move comes after the company's Phase 3
Bellini trial saw more deaths from the arm of the trial using
venetoclax when compared with the trial's controlled arm.
AbbVie said "no new patients should be enrolled in any studies
of venetoclax for multiple myeloma until a further analysis of the
data is completed."
The company said the FDA's partial hold doesn't affect
indications for which venetoclax has already been approved.
AbbVie is developing venetoclax with Roche Holding AG.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
March 19, 2019 09:49 ET (13:49 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2023 to Mar 2024